相关实验视频

Updated: May 31, 2025

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

达拉图穆马布在复发性/耐火性多发性髓瘤患者的治疗中是否有作用?

Davor Galusic^1,2, Ivan Krecak^3,4,5, Viktor Blaslov¹

¹Division of Hematology, University Hospital of Split, 21000 Split, Croatia.

|January 25, 2025

概括

对复发性/耐药性多发性骨髓瘤 (MM) 患者,达拉图穆马布重复治疗提供了临床益处. 大约一半的人实现了部分缓解,在重度预治疗的个体中显示了持久的反应.

科学领域:

血液学血液学血液学
免疫治疗是一种免疫疗法.
在瘤学瘤学.

背景情况:

多发性髓瘤 (MM) 是一种血细胞恶性瘤,导致骨病,高血症,贫血和功能障碍.
反CD38单克隆抗体达拉图马布 (Daratumumab) 已被批准用于MM治疗,影响一线和复发/耐药设置.
关于达拉图穆马布再治疗疗效的数据有限,特别是考虑到像双特异性T细胞重定向抗体 (BsAbs) 和CAR-T疗法等新疗法的成本和可用性.

研究的目的:

对复发/耐药多发性骨髓瘤患者的达拉图巴再治疗的疗效和结果进行现有文献的审查.
为了评估患者接受后续线程治疗的daratumumab的响应率和治疗持续时间.

主要方法:

关于对现实世界医疗记录的回顾性分析的文献综述.
鉴定和综合关于达拉图穆马布再治疗反应率和治疗持续时间的数据.

主要成果:

追溯分析显示,在重度预先治疗的MM患者中,疗效一致.
大约50%的患者在重新治疗达拉图穆马布后至少实现了部分缓解 (PR).
治疗持续时间和到下一次治疗的时间在临床上对后期疗法有意义.

结论:

重复治疗达拉图姆可以为选择复发性/耐药性MM患者提供显著的临床益处,即使在先前暴露后也是如此.
需要进一步的研究,以确定可预测的生物标志物,以便对达拉图穆马布再治疗产生有利的反应.

关键词:

在达拉图穆巴马布.多发性骨髓瘤是多发性骨髓瘤的一种.这是一个复发的复发.进行再处理.

更多相关视频

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...